Huaren Health released its 2026 interim report, with total operating revenue of 2.825 billion yuan and net profit attributable to the parent company of 136 million yuan. Net cash inflow from operating activities was 410 million yuan, down 22.95% from the same period last year. The company's asset-liability ratio was 60.25%, gross margin was 34.72%, ROE was 6.41%, and diluted earnings per share was 0.34 yuan. The number of shareholders was 29,100, and the top ten shareholders held 65.97% of the total share capital.
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl AInterim report shows net profit of 136 million yuan, indicating profitability.